Ioflupane I 123

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 341355

CAS#: 155798-07-5

Description: Ioflupane I 123 is the International Nonproprietary Name of a phenyltropane compound which is a neuro-imaging radiopharmaceutical drug, used by nuclear medicine physicians for the diagnosis of Parkinson's disease and the differential diagnosis of Parkinson's disease over other disorders presenting similar symptoms.

Chemical Structure

img
Ioflupane I 123
CAS# 155798-07-5
Instruction

Theoretical Analysis

MedKoo Cat#: 341355
Name: Ioflupane I 123
CAS#: 155798-07-5
Chemical Formula: C18H23F123INO2
Exact Mass: 427.08
Molecular Weight: 427.291
Elemental Analysis: C, 50.60; H, 5.43; F, 4.45; I, 28.76; N, 3.28; O, 7.49

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Ioflupane I 123; Ioflupane; V 09AB03; V-09AB03; V09AB03.

IUPAC/Chemical Name: Methyl 8-(3-fluoropropyl)-3beta-(p-iodo-I(sup 123)-phenyl)-1alphaH, 5alphaH-nortropane-2beta-carboxylate

InChi Key: HXWLAJVUJSVENX-HFIFKADTSA-N

InChi Code: InChI=1S/C18H23FINO2/c1-23-18(22)17-15(12-3-5-13(20)6-4-12)11-14-7-8-16(17)21(14)10-2-9-19/h3-6,14-17H,2,7-11H2,1H3/t14-,15+,16+,17-/m0/s1/i20-4

SMILES Code: COC(=O)[C@@H]1[C@H]2CC[C@H](N2CCCF)C[C@@H]1c3ccc(cc3)[123I]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 427.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Thobois S, Prange S, Scheiber C, Broussolle E. What a neurologist should know about PET and SPECT functional imaging for parkinsonism: A practical perspective. Parkinsonism Relat Disord. 2018 Aug 30. pii: S1353-8020(18)30375-4. doi: 10.1016/j.parkreldis.2018.08.016. [Epub ahead of print] PubMed PMID: 30181086.

2: Okada Y, Shiraishi M, Nakamura H, Maki F, Sasaki N, Hasegawa Y, Sasaki O, Nakashima Y. Usefulness of the combination of iodine-123-metaiodobenzylguanidine scintigraphy and iodine-123-ioflupane scintigraphy in new-onset Parkinson's disease. Nucl Med Commun. 2018 Sep 1. doi: 10.1097/MNM.0000000000000898. [Epub ahead of print] PubMed PMID: 30180045.

3: Murakami H, Yamamoto K, Yasumoto T, Kimura A, Sakae Y, Nomoto S, Kubota S, Watanabe D, Watanabe K, Saito Y, Yano S, Ono K. Cerebrospinal fluid 5-HIAA concentrations correlate with cardiac uptake of (123)I-MIBG during myocardial scintigraphy in drug naïve Parkinson's disease. J Neural Transm (Vienna). 2018 Oct;125(10):1511-1514. doi: 10.1007/s00702-018-1917-x. Epub 2018 Aug 23. PubMed PMID: 30167932.

4: Kuo PH, Eshghi N, Tinaz S, Blumenfeld H, Louis ED, Zubal G. Optimization of Parameters for Quantitative Analysis of (123)I-ioflupane SPECT Images for Monitoring of Progression of Parkinson's Disease. J Nucl Med Technol. 2018 Aug 23. pii: jnmt.118.213181. doi: 10.2967/jnmt.118.213181. [Epub ahead of print] PubMed PMID: 30139881.

5: Kim DH, Wit H, Thurston M. Artificial intelligence in the diagnosis of Parkinson's disease from ioflupane-123 single-photon emission computed tomography dopamine transporter scans using transfer learning. Nucl Med Commun. 2018 Oct;39(10):887-893. doi: 10.1097/MNM.0000000000000890. PubMed PMID: 30080748.

6: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK501915/ PubMed PMID: 30000975.

7: Carrasco García de León S, Cabello JP, Ortiz R, Vaamonde J. Parkinsonism Associated with Pathological 123I-FP-CIT SPECT (DaTSCAN) Results as the Initial Manifestation of Sporadic Creutzfeldt-Jakob Disease. Case Rep Neurol Med. 2018 May 31;2018:5157275. doi: 10.1155/2018/5157275. eCollection 2018. PubMed PMID: 29955403; PubMed Central PMCID: PMC6000879.

8: Matesan M, Gaddikeri S, Longfellow K, Miyaoka R, Elojeimy S, Elman S, Hu SC, Minoshima S, Lewis D. I-123 DaTscan SPECT Brain Imaging in Parkinsonian Syndromes: Utility of the Putamen-to-Caudate Ratio. J Neuroimaging. 2018 Jun 14. doi: 10.1111/jon.12530. [Epub ahead of print] PubMed PMID: 29905019.

9: Nichols KJ, Chen B, Tomas MB, Palestro CJ. Interpreting (123)I-ioflupane dopamine transporter scans using hybrid scores. Eur J Hybrid Imaging. 2018;2(1):10. doi: 10.1186/s41824-018-0028-0. Epub 2018 May 21. PubMed PMID: 29855627; PubMed Central PMCID: PMC5960650.

10: Skogseid IM, Røsby O, Konglund A, Connelly JP, Nedregaard B, Jablonski GE, Kvernmo N, Stray-Pedersen A, Glover JC. Dystonia-deafness syndrome caused by ACTB p.Arg183Trp heterozygosity shows striatal dopaminergic dysfunction and response to pallidal stimulation. J Neurodev Disord. 2018 May 22;10(1):17. doi: 10.1186/s11689-018-9235-z. PubMed PMID: 29788902; PubMed Central PMCID: PMC5964724.

11: Fukuoka T, Nakazato Y, Yamamoto M, Miyake A, Mitsufuji T, Yamamoto T. Fatal Familial Insomnia Initially Developing Parkinsonism Mimicking Dementia with Lewy Bodies. Intern Med. 2018 Sep 15;57(18):2719-2722. doi: 10.2169/internalmedicine.0573-17. Epub 2018 Apr 27. PubMed PMID: 29709939.

12: Kotagal V, Spino C, Bohnen NI, Koeppe R, Albin RL. Serotonin, β-amyloid, and cognition in Parkinson disease. Ann Neurol. 2018 May;83(5):994-1002. doi: 10.1002/ana.25236. Epub 2018 May 11. PubMed PMID: 29665066; PubMed Central PMCID: PMC6021203.

13: Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun D, Poston K, Arnedo V, Frasier M, Sherer T, Chowdhury S, Marek K; Parkinson's Progression Marker Initiative*. Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. Mov Disord. 2018 May;33(5):771-782. doi: 10.1002/mds.27361. Epub 2018 Mar 23. PubMed PMID: 29572948; PubMed Central PMCID: PMC6001458.

14: Nuvoli S, Palumbo B, Malaspina S, Madeddu G, Spanu A. (123)I-ioflupane SPET and (123)I-MIBG in the diagnosis of Parkinson's disease and parkinsonian disorders and in the differential diagnosis between Alzheimer's and Lewy's bodies dementias. Hell J Nucl Med. 2018 Jan-Apr;21(1):60-68. doi: 10.1967/s002449910707. Epub 2018 Mar 20. Review. PubMed PMID: 29550847.

15: Langston JW, Wiley JC, Tagliati M. Optimizing Parkinson's disease diagnosis: the role of a dual nuclear imaging algorithm. NPJ Parkinsons Dis. 2018 Feb 23;4:5. doi: 10.1038/s41531-018-0041-9. eCollection 2018. Review. PubMed PMID: 29507872; PubMed Central PMCID: PMC5824845.

16: Royston EJ, Kao YE, Nakamura KM. DaT's Awesome: Hawai'i's First Dopamine Transporter (DaT) Nuclear Medicine Study. Hawaii J Med Public Health. 2017 Nov;76(11 Suppl 2):16-18. PubMed PMID: 29164011; PubMed Central PMCID: PMC5696590.

17: Bhattacharjee S, Chalissery AJ, Barry T, O'Sullivan D, O'Connell M, Lynch T. Referral practice, reporting standards, and the impact of dopamine transporter scans done in a tertiary hospital. Neurol India. 2017 Nov-Dec;65(6):1264-1270. doi: 10.4103/0028-3886.217946. PubMed PMID: 29133699.

18: Reams N, Anderson J, Perlman R, Li W, Walters S, Tideman S, Wang C, Simon K, Frigerio R, Maraganore DM. Investigating ioflupane I(123) injection and single photon emission tomography as an imaging biomarker for long-term sequelae following mild traumatic brain injury. Brain Inj. 2018;32(1):105-112. doi: 10.1080/02699052.2017.1388443. Epub 2017 Nov 13. PubMed PMID: 29131690.

19: Pagano G, Yousaf T, Wilson H, Niccolini F, Polychronis S, Chaudhuri KR, Politis M. Constipation is not associated with dopamine transporter pathology in early drug-naïve patients with Parkinson's disease. Eur J Neurol. 2018 Feb;25(2):307-312. doi: 10.1111/ene.13503. Epub 2017 Dec 11. PubMed PMID: 29078029.

20: Mansu Kim, Seong-Jin Son, Hyunjin Park. Imaging genetics approach to predict progression of Parkinson's diseases. Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:3922-3925. doi: 10.1109/EMBC.2017.8037714. PubMed PMID: 29060755.